NEW YORK, Jan. 12, 2021 (GLOBE NEWSWIRE) — Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Fortress Biotech, Inc. (NASDAQ: FBIO) from December 11, 2019 through October 9, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Fortress Biotech, Inc. investors under the federal securities laws.

To join the class action, go

here

or call Vik Pawar, Esq. toll-free at 888-589-9804 or email

[email protected]

for information on the class action.

According to the lawsuit,  defendants made false and/or misleading statements and/or failed to disclose that: (1) IV Tramadol was not safe for the intended patient population; (2) as a result, it was foreseeable that the FDA would not approve the NDA for IV Tramadol; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.

If you wish to serve as lead plaintiff, you must move the Court no later than

January 26, 2021

. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Vik Pawar, Esq.

Pawar Law Group

20 Vesey Street, Suite 1410

New York, NY 10007

Tel: (917) 261-2277

Fax: (212) 571-0938

[email protected]